Monday’s Top Health Care Stories: Pfizer, AstraZeneca, Mylan, Forest, and Furiex

Keep a close eye on Pfizer, AstraZeneca, Mylan, Forest, and Furiex this morning.

Apr 28, 2014 at 9:19AM


Let's check in on four companies -- Pfizer (NYSE:PFE), AstraZeneca (NYSE:AZN), Mylan (NASDAQ:MYL), Forest Labs (NYSE:FRX) and Furiex Pharmaceuticals (UNKNOWN:FURX.DX) -- all of which could make waves across the health care sector this Monday morning.

Pfizer confirms its renewed interest in AstraZeneca
First and foremost, Pfizer just confirmed its desire to acquire British pharmaceutical giant AstraZeneca. Pfizer stated that it initially made a bid for AstraZeneca in January, and approached the company again on April 26 to renew discussions regarding a potential takeover. Shares of AstraZeneca are up more than 16% in pre-market trading in response to the announcement, while shares of Pfizer are up nearly 3%.

Pfizer's initial offer on January 5, which consisted of a cash and stock offer in the combined entity, would have represented a value of £46.61 ($76.62) per AstraZeneca share -- a 30% premium over its closing price on January 3. The deal would have been one of the largest pharma deals in history with a value of nearly $100 billion.

Pfizer has been streamlining its operations ever since the 2011 patent expiration of its blockbuster cholesterol drug Lipitor, which generated peak sales of $13 billion. Pfizer strengthened its pipeline with new cancer and cholesterol drugs, sold its infant nutrition business, spun off its animal health unit as Zoetis, and has indicated ultimately that it may split its business into three distinct units -- two for branded products and one for generics.

AstraZeneca has also struggled with similar issues as Pfizer. Over the next three years, it will lose patent protection for its blockbuster cholesterol drug Crestor and the antipsychotic Seroquel, which generated combined sales of nearly $7 billion in 2013. To offset those losses, AstraZeneca strengthened its pipeline of experimental cancer immunotherapy drugs -- which are considered a top draw for Pfizer -- and acquired Bristol Myers-Squibb's stake in their joint diabetes venture last December.

Meda rejects Mylan's takeover bid
In other M&A news, Swedish pharmaceutical company Meda slipped 9% in Stockholm earlier today after the company rejected a takeover bid from Mylan worth over $9 billion. Shares of Mylan were also down 9% in pre-market trading, but have since slightly recovered.

Meda's board rejected Mylan's proposal for the second time in a month, and stated that all talks between the two companies have ended. A lack of "sufficient support" from Meda's largest shareholder, Swedish shipping company Stena Sessan, was cited as the primary reason for the rejection.

Meda -- which holds a diverse portfolio of specialty pharmaceuticals and over-the-counter products -- has been considered a lucrative acquisition target for some time. Last year, the company rejected a takeover bid from Indian generics maker Sun Pharma.

Acquiring Meda would have represented a major overseas expansion for Mylan, which generates nearly half of its sales within the United States. Mylan has recently made headway in India as Gilead Sciences' exclusive partner for branded medicines in India. It also recently launched a biosimilar version of Roche's breast cancer drug Herceptin in India with Biocon.

Forest Labs acquires Furiex Pharmaceuticals
Last but not least, Forest Labs just announced that it entered a definitive agreement to acquire Furiex, a drug development collaboration company, for up to $1.46 billion. The deal will expand Forest's growing GI (gastrointestinal) disease treatment business, which is anchored by Linzess, a treatment for constipation related to irritable bowel syndrome, and was significantly expanded through its $2.9 billion acquisition of Aptalis earlier this year.

The deal will value Furiex at $95 per share ($1.1 billion in cash) and up to $30 per share ($360 million) payable depending upon the status of Furiex's lead product eluxadoline, a treatment for diarrhea-predominant irritable bowel syndrome. Analysts at Canaccord Genuity forecast the drug to generate peak sales of $745 million in the U.S. if approved.

Forest simultaneously announced that it entered an agreement with Royalty Pharma to sell Furiex's royalties on alogliptin and Priligy to Royalty for approximately $415 million upon the successful completion of the Furiex acquisition.

Shares of Furiex are up nearly 30% in pre-market trading, although shares of Forest Labs remain unchanged.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Leo Sun owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information